Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

112 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Correction to: LHRH sparing therapy in patients with chemotherapy-naïve, mCRPC treated with abiraterone acetate plus prednisone: results of the randomized phase II SPARE trial.
Ohlmann CH, Jäschke M, Jaehnig P, Krege S, Gschwend J, Rexer H, Junker K, Zillmann R, Rüssel C, Hellmis E, Suttmann H, Janssen M, Marin J, Hübner A, Mathers M, Gleißner J, Scheffler M, Feyerabend S, Telle J, Klier J, Stöckle M. Ohlmann CH, et al. Among authors: rexer h. Prostate Cancer Prostatic Dis. 2023 Dec;26(4):812. doi: 10.1038/s41391-023-00682-2. Prostate Cancer Prostatic Dis. 2023. PMID: 37253975 Free PMC article. No abstract available.
LHRH sparing therapy in patients with chemotherapy-naïve, mCRPC treated with abiraterone acetate plus prednisone: results of the randomized phase II SPARE trial.
Ohlmann CH, Jäschke M, Jaehnig P, Krege S, Gschwend J, Rexer H, Junker K, Zillmann R, Rüssel C, Hellmis E, Suttmann H, Janssen M, Marin J, Hübner A, Mathers M, Gleißner J, Scheffler M, Feyerabend S, Telle J, Klier J, Stöckle M. Ohlmann CH, et al. Among authors: rexer h. Prostate Cancer Prostatic Dis. 2022 Apr;25(4):778-784. doi: 10.1038/s41391-022-00533-6. Epub 2022 Apr 16. Prostate Cancer Prostatic Dis. 2022. PMID: 35430584 Free PMC article. Clinical Trial.
Abiraterone acetate plus LHRH therapy versus abiraterone acetate while sparing LHRH therapy in patients with progressive, metastatic and chemotherapy-naïve, castration-resistant prostate cancer (SPARE): study protocol for a randomized controlled trial.
Ohlmann CH, Jäschke M, Jaehnig P, Krege S, Gschwend J, Rexer H, Stöckle M. Ohlmann CH, et al. Among authors: rexer h. Trials. 2017 Oct 4;18(1):457. doi: 10.1186/s13063-017-2195-x. Trials. 2017. PMID: 28978327 Free PMC article. Clinical Trial.
Erstlinientherapie beim lokal fortgeschrittenen oder metastasierten Urothelkarzinom: Eine randomisierte, doppelblinde Phase-III-Multicenterstudie zur adjuvanten Nivolumab-Therapie versus Placebo bei Patienten mit invasivem Hochrisiko-Urothelkarzinom (CheckMate 274) – AB 58/17 der AUO.
Rexer H, Ohlmann CH, Gschwend J. Rexer H, et al. Aktuelle Urol. 2018 Aug;49(4):308-309. doi: 10.1055/a-0633-7395. Epub 2018 Aug 7. Aktuelle Urol. 2018. PMID: 30086585 German. No abstract available.
Versorgungsforschung in der Uroonkologie – Von der Last zur Lust auf Daten.
König F, Johannsen M, Klier J, Schönfelder R, Eichenauer R, Rexer H, Gschwend J, Suttmann H, Doehn C. König F, et al. Among authors: rexer h. Aktuelle Urol. 2018 Apr;49(2):125. doi: 10.1055/s-0044-101694. Epub 2018 Mar 27. Aktuelle Urol. 2018. PMID: 29587317 German. No abstract available.
The Diagnosis, Treatment, and Follow-up of Renal Cell Carcinoma.
Doehn C, Grünwald V, Steiner T, Follmann M, Rexer H, Krege S. Doehn C, et al. Among authors: rexer h. Dtsch Arztebl Int. 2016 Sep 5;113(35-36):590-6. doi: 10.3238/arztebl.2016.0590. Dtsch Arztebl Int. 2016. PMID: 27658472 Free PMC article. Review.
112 results